[태그:] GLP-1

Amgen MariTide Obesity Phase 3 Readout Impact on Stock 2026: Why a $415 Base Case Rests on the $100B Weight-Loss Optionality

Amgen (AMGN) trades at a 15.6x forward P/E while its base business grows double digits and MariTide gives a near-free obesity option. Base case $415, Buy.

미국 주식 분석

Eli Lilly Stock Analysis: The GLP-1 Giant Entering a New Era of Growth with Oral Obesity Drug Approval

Eli Lilly stock analysis: FDA approved Foundayo oral GLP-1 pill, 57% market share, B 2026 revenue guidance. Target price ,080 with 17% upside.

검색